ArticleDiabetes, obesity & metabolism2018

The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.

Russell Drummond et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.